Skip to navigation Skip to content

News

Share

An FDA Approved Generic Form of Ampyra® (dalfampridine) Is Launched in the U.S.

October 19, 2018

A generic equivalent of Ampyra (dalfampridine), a treatment that is approved to improve walking in adults with MS, has been approved by the U.S. Food and Drug Administration and launched by Mylan NV. Dalfampridine extended-release tables 10 mg are currently available. Details on price have not been provided.

Dalfampridine is approved by the FDA to improve walking in people with MS. Possible adverse events include seizures, urinary tract infection, nausea, dizziness, insomnia and upper respiratory tract infection. This approval means that Mylan provided evidence that this generic medication is equivalent to Ampyra.

Selecting a therapy should be done by people with MS in collaboration with their MS doctors, taking into account a variety of factors, including the effectiveness of any therapy they are currently using, and weighing potential risks and benefits, costs and lifestyle factors.

Read more
Read the dalfampridine medication guide for patients
View the dalfampridine prescription label
 
Frequently Asked Questions: Generic and Biosimilar - Medications

About Multiple Sclerosis

Multiple sclerosis is an unpredictable disease of the central nervous system. Currently there is no cure. Symptoms vary from person to person and may include disabling fatigue, mobility challenges, cognitive changes, and vision issues. An estimated 1 million people live with MS in the United States. Early diagnosis and treatment are critical to minimize disability. Significant progress is being made to achieve a world free of MS.

Share


© 2022 The National Multiple Sclerosis Society is a tax exempt 501(c)3 nonprofit organization. Its Identification Number (EIN) is 13-5661935.